- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00288132
The Diabetes TeleCare Study (DTC)
Bridging Barriers to Diabetes Care With Telemedicine: The Diabetes TeleCare Study (DTC)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
According to recent 2002 estimates, the yearly cost of diabetes was approximately $132 billion. The burden of diabetes is considerable, particularly for ethnically diverse populations. Disease management programs that focus on self-management education have been effective in improving metabolic control. Accordingly, the American Diabetes Association clinical care guidelines stress the importance of metabolic control to prevent complications and improve quality of life for persons with this disease. Unfortunately, these advances have not resulted in widespread acceptance into clinical practice. Therefore, we propose translational research to evaluate telemedicine technology using interactive video conferencing (Diabetes TeleCare) as a novel means to increase the availability of health professionals in rural communities for the effective delivery of a diabetes self-management education program and as a means to provide retinal screenings in the primary care setting. Our aims are to 1) develop and implement a 12-month intervention, Diabetes TeleCare to improve adherence to diabetes clinical care guidelines and improve diabetes control in two community health centers located in ethnically diverse, rural and medically underserved communities, 2) conduct a one-year randomized clinical trial (RCT) of 200 patients to formally evaluate the effectiveness of Diabetes TeleCare compared to Usual Care in a sample with >60% African-Americans, and 3) determine the cost-effectiveness and satisfaction of Diabetes TeleCare compared to Usual Care. Participants are recruited from two community health centers in rural South Carolina and randomized according to a patient randomization schedule. Diabetes TeleCare (a structured curriculum) is delivered by a team consisting of a registered nurse/certified diabetes educator (RN-CDE) and an experienced registered dietitian, with support by other health professionals who are linked by interactive video conferencing to participants (single and group) in rural health centers at distant locations. The primary outcomes are measures of metabolic control (A1c, lipids), blood pressure, and use of the telemedicine-facilitated retinal screening capacity. Secondary outcomes include satisfaction, quality of life, health beliefs, and knowledge. The economic analysis will include an assessment of resource utilization, cost, and health utilities. In addition, incremental reductions in costs per A1c and the estimated lifetime cost-utility of Diabetes TeleCare compared to usual care will be determined. Telemedicine may be an effective alternative to traditional health care delivery systems resulting in improved diabetes education and control.
The intervention goal was to achieve an A1c <7%, with secondary goals of 10% weight loss and increasing exercise to at least 30 minutes a day, 5 days a week. Participants attend 13 sessions, 2 in the first month (1 group, 1 individual), monthly thereafter (9 group, 2 individual). Three group sessions were conducted in-person, all others were conducted via telemedicine. The self-management education team consisted of an RN/CDE and an RD. Sessions were conducted remotely, with a trained facilitator (LPN) at the clinic site. Participants were given a notebook and new material was added at each session. Completion of self-monitoring logs, including blood sugar, diet and physical activity, was assigned daily followed by less frequently based on progress towards intervention goals.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
South Carolina
-
Bennettsville, South Carolina, Stati Uniti, 29512
- CareSouth Bennettsville
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- All participants must have a confirmed physician diagnosis of type 2 diabetes supported by American Diabetes Association diagnostic criteria for blood glucose levels or
- Current use of oral hypoglycemic agents or insulin as confirmed by brief medical record review.
- All adults (> 21 years of age) who have a A1c value > 7.0 will be eligible.
Exclusion Criteria:
Exclusion criteria applies to individuals with limitations that could limit safe participation in the study,
- such as metastatic cancer,
- multiple or recent (within six months) myocardial infarction (MI) or stroke,
- dialysis for end stage renal disease,
- severe psychiatric disease or dementia, or
- inability to walk without an assistive device.
- We will also exclude women who are pregnant at the time of study recruitment (based on self report only) because of the unique needs related to diabetes self-management during pregnancy.
- We will, however, retain women in the study should they become pregnant during the course of the project.
- Individuals will be excluded if they plan to move out of the area.
- Additional exclusions may include inability to complete baseline tasks to the satisfaction of the lead interventionist or other more subjective assessment suggesting inability or unwillingness to adhere reasonably to the intervention based on interventionist review.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Intervento
|
A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted.
|
|
Comparatore attivo: Solita cura
|
Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials.
Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Hemoglobin A1c
Lasso di tempo: 6 mths, 12 mths, 24 mths
|
6 mths, 12 mths, 24 mths
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Blood pressure
Lasso di tempo: 6 mths, 12 mths, 24 mths
|
6 mths, 12 mths, 24 mths
|
|
LDL Cholesterol
Lasso di tempo: 6 mths, 12 mths, 24 mths
|
6 mths, 12 mths, 24 mths
|
|
Cost effectiveness and cost utility
Lasso di tempo: 6 mths, 12 mths
|
6 mths, 12 mths
|
|
Retinal examination rates
Lasso di tempo: 12 months
|
12 months
|
|
Weight
Lasso di tempo: 6 mths, 12 mths, 24 mths
|
6 mths, 12 mths, 24 mths
|
|
Waist Circumference
Lasso di tempo: 6 mths, 12 mths, 24 mths
|
6 mths, 12 mths, 24 mths
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Richard M Davis, MD, University of South Carolina
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- R18 67312 (completed)
- R18DK067312 (Sovvenzione/contratto NIH degli Stati Uniti)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .